A. Romano Kathryn's most recent trade in Krystal Biotech Inc was a trade of 10,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 7,500 | 22,789 (0%) | 0% | 0 | Common Stock | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 7,500 | 7,500 | - | - | Performance Stock Units | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 5,000 | 17,604 (0%) | 0% | 0 | Common Stock | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 5,000 | 0 | - | - | Performance Stock Units | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 179.25 per share. | 26 Feb 2025 | 3,471 | 19,318 (0%) | 0% | 179.3 | 622,177 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 179.25 per share. | 26 Feb 2025 | 2,315 | 15,289 (0%) | 0% | 179.3 | 414,964 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 176.39 per share. | 26 Feb 2025 | 2,268 | 13,354 (0%) | 0% | 176.4 | 400,053 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 2,200 | 2,200 | - | - | Restricted Stock Units | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 175.22 per share. | 26 Feb 2025 | 750 | 12,604 (0%) | 0% | 175.2 | 131,415 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 15,000 | 15,000 | - | - | Performance Stock Units | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 5,000 | 17,936 (0%) | 0% | 0 | Common Stock | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 5,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 5,000 | 5,000 | - | - | Performance Stock Units | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 5,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 2,500 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 163.08 per share. | 28 Feb 2024 | 2,314 | 15,622 (0%) | 0% | 163.1 | 377,367 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 1,600 | 14,536 (0%) | 0% | 63.6 | 101,680 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 164.84 per share. | 28 Feb 2024 | 1,600 | 12,936 (0%) | 0% | 164.8 | 263,751 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 1,429 | 14,365 (0%) | 0% | 63.6 | 90,813 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 164.81 per share. | 28 Feb 2024 | 1,429 | 12,936 (0%) | 0% | 164.8 | 235,510 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 1,216 | 14,152 (0%) | 0% | 63.6 | 77,277 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 169.09 per share. | 28 Feb 2024 | 1,216 | 12,936 (0%) | 0% | 169.1 | 205,619 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 1,133 | 14,069 (0%) | 0% | 63.5 | 72,002 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 169.10 per share. | 28 Feb 2024 | 1,133 | 12,936 (0%) | 0% | 169.1 | 191,585 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 900 | 13,836 (0%) | 0% | 63.6 | 57,195 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 163.68 per share. | 28 Feb 2024 | 900 | 12,936 (0%) | 0% | 163.7 | 147,308 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 786 | 13,722 (0%) | 0% | 63.5 | 49,950 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 163.49 per share. | 28 Feb 2024 | 786 | 12,936 (0%) | 0% | 163.5 | 128,506 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 744 | 13,680 (0%) | 0% | 63.5 | 47,281 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 164.60 per share. | 28 Feb 2024 | 744 | 12,936 (0%) | 0% | 164.6 | 122,465 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 700 | 13,636 (0%) | 0% | 63.6 | 44,485 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 168.91 per share. | 28 Feb 2024 | 700 | 12,936 (0%) | 0% | 168.9 | 118,240 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 648 | 13,584 (0%) | 0% | 63.5 | 41,180 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 162.71 per share. | 28 Feb 2024 | 648 | 12,936 (0%) | 0% | 162.7 | 105,436 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 637 | 13,573 (0%) | 0% | 63.5 | 40,481 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 162.73 per share. | 28 Feb 2024 | 637 | 12,936 (0%) | 0% | 162.7 | 103,656 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 523 | 13,459 (0%) | 0% | 63.6 | 33,237 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 163.13 per share. | 28 Feb 2024 | 523 | 12,936 (0%) | 0% | 163.1 | 85,319 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 300 | 13,236 (0%) | 0% | 63.6 | 19,065 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 166.06 per share. | 28 Feb 2024 | 300 | 12,936 (0%) | 0% | 166.1 | 49,819 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 300 | 13,236 (0%) | 0% | 63.6 | 19,065 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 167.85 per share. | 28 Feb 2024 | 300 | 12,936 (0%) | 0% | 167.9 | 50,355 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 300 | 13,236 (0%) | 0% | 63.6 | 19,065 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 167.85 per share. | 28 Feb 2024 | 300 | 12,936 (0%) | 0% | 167.9 | 50,355 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 210 | 13,146 (0%) | 0% | 63.6 | 13,346 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 169.75 per share. | 28 Feb 2024 | 210 | 12,936 (0%) | 0% | 169.8 | 35,648 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 203 | 13,139 (0%) | 0% | 63.6 | 12,901 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 169.47 per share. | 28 Feb 2024 | 203 | 12,936 (0%) | 0% | 169.5 | 34,402 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 200 | 13,136 (0%) | 0% | 63.6 | 12,710 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 166.04 per share. | 28 Feb 2024 | 200 | 12,936 (0%) | 0% | 166.0 | 33,208 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 134 | 13,070 (0%) | 0% | 63.6 | 8,516 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 171.66 per share. | 28 Feb 2024 | 134 | 12,936 (0%) | 0% | 171.7 | 23,002 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 130 | 13,066 (0%) | 0% | 63.6 | 8,262 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 165.22 per share. | 28 Feb 2024 | 130 | 12,936 (0%) | 0% | 165.2 | 21,479 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 117 | 13,053 (0%) | 0% | 63.5 | 7,435 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 169.82 per share. | 28 Feb 2024 | 117 | 12,936 (0%) | 0% | 169.8 | 19,869 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 100 | 13,036 (0%) | 0% | 63.6 | 6,355 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 166.22 per share. | 28 Feb 2024 | 100 | 12,936 (0%) | 0% | 166.2 | 16,622 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 28 Feb 2024 | 100 | 13,036 (0%) | 0% | 63.6 | 6,355 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 171.45 per share. | 28 Feb 2024 | 100 | 12,936 (0%) | 0% | 171.5 | 17,145 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.56 per share. | 28 Feb 2024 | 90 | 13,026 (0%) | 0% | 63.6 | 5,720 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 172.23 per share. | 28 Feb 2024 | 90 | 12,936 (0%) | 0% | 172.2 | 15,501 | Common Stock |
| Krystal Biotech Inc | Romano Kathryn A. | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 135.00 per share. | 26 Feb 2024 | 5,000 | 12,556 (0%) | 0% | 135 | 675,000 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.26 per share. | 26 Feb 2024 | 5,000 | 17,556 (0%) | 0% | 52.3 | 261,300 | Common Stock |
| Krystal Biotech Inc | A. Romano Kathryn | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 5,000 | 5,000 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.26 per share. | 26 Feb 2024 | 3,087 | 15,643 (0%) | 0% | 52.3 | 161,327 | Common Stock |
| Krystal Biotech Inc | Romano Kathryn A. | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 3,087 | 1,913 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Romano A. Kathryn | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 140.00 per share. | 26 Feb 2024 | 3,087 | 12,556 (0%) | 0% | 140 | 432,180 | Common Stock |
| Krystal Biotech Inc | A. Kathryn Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 1,913 | 0 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | A. Romano Kathryn | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.26 per share. | 26 Feb 2024 | 1,913 | 12,936 (0%) | 0% | 52.3 | 99,973 | Common Stock |
| Krystal Biotech Inc | Kathryn Romano A. | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.00 per share. | 26 Feb 2024 | 1,533 | 11,023 (0%) | 0% | 157 | 240,681 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.26 per share. | 22 Jan 2024 | 2,500 | 15,056 (0%) | 0% | 52.3 | 130,650 | Common Stock |
| Krystal Biotech Inc | Romano Kathryn A. | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 2,500 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | A. Kathryn Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 130.00 per share. | 22 Jan 2024 | 2,500 | 12,556 (0%) | 0% | 130 | 325,000 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2023 | 12,500 | 37,500 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2023 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2023 | 12,500 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2023 | 12,500 | 37,500 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 110.00 per share. | 19 May 2023 | 12,500 | 12,556 (0%) | 0% | 110 | 1,375,000 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.55 per share. | 19 May 2023 | 12,500 | 25,056 (0%) | 0% | 63.6 | 794,375 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 95.04 per share. | 19 May 2023 | 12,500 | 15,984 (0%) | 0% | 95.0 | 1,188,061 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.26 per share. | 19 May 2023 | 12,500 | 28,484 (0%) | 0% | 52.3 | 653,250 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 95.05 per share. | 19 May 2023 | 12,500 | 15,984 (0%) | 0% | 95.1 | 1,188,125 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.26 per share. | 19 May 2023 | 12,500 | 28,484 (0%) | 0% | 52.3 | 653,250 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 95.08 per share. | 19 May 2023 | 3,428 | 12,556 (0%) | 0% | 95.1 | 325,937 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 109.99 per share. | 19 May 2023 | 3,154 | 12,556 (0%) | 0% | 110.0 | 346,919 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.26 per share. | 19 May 2023 | 3,154 | 15,710 (0%) | 0% | 52.3 | 164,828 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 109.17 per share. | 19 May 2023 | 2,955 | 12,556 (0%) | 0% | 109.2 | 322,603 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.26 per share. | 19 May 2023 | 2,955 | 15,511 (0%) | 0% | 52.3 | 154,428 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 106.81 per share. | 19 May 2023 | 2,570 | 12,556 (0%) | 0% | 106.8 | 274,498 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.26 per share. | 19 May 2023 | 2,570 | 15,126 (0%) | 0% | 52.3 | 134,308 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 105.80 per share. | 19 May 2023 | 2,521 | 12,556 (0%) | 0% | 105.8 | 266,731 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.26 per share. | 19 May 2023 | 2,521 | 15,077 (0%) | 0% | 52.3 | 131,747 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 107.88 per share. | 19 May 2023 | 1,300 | 12,556 (0%) | 0% | 107.9 | 140,241 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.26 per share. | 19 May 2023 | 1,300 | 13,856 (0%) | 0% | 52.3 | 67,938 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2023 | 10,000 | 10,000 | - | - | Performance Stock Units | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.46 per share. | 26 Feb 2023 | 2,144 | 15,984 (0%) | 0% | 78.5 | 168,218 | Common Stock |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Kathryn A. Romano | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.50 per share. | 26 Feb 2022 | 1,472 | 18,128 (0%) | 0% | 62.5 | 92,000 | Common Stock |